NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
<p dir="ltr">NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, h...
محفوظ في:
| المؤلف الرئيسي: | Remy Thomas (702843) (author) |
|---|---|
| مؤلفون آخرون: | Ghaneya Al-Khadairi (14153274) (author), Jessica Roelands (7516439) (author), Wouter Hendrickx (44559) (author), Said Dermime (79420) (author), Davide Bedognetti (2632474) (author), Julie Decock (44558) (author) |
| منشور في: |
2018
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
مواد مشابهة
-
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
حسب: Afsheen Raza (492657)
منشور في: (2022) -
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
حسب: Remy Thomas (702843)
منشور في: (2020) -
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
حسب: Ghaneya Al-Khadairi (14153274)
منشور في: (2019) -
Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
حسب: Nassiba Taib (14557385)
منشور في: (2023) -
Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
حسب: Maysaloun Merhi (4246147)
منشور في: (2018)